Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Retained Earnings: 2014-2025

Historic Retained Earnings for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to -$920.7 million.

  • Theravance Biopharma's Retained Earnings rose 3.09% to -$920.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$920.7 million, marking a year-over-year increase of 3.09%. This contributed to the annual value of -$965.5 million for FY2024, which is 6.21% down from last year.
  • Latest data reveals that Theravance Biopharma reported Retained Earnings of -$920.7 million as of Q3 2025, which was up 0.39% from -$924.3 million recorded in Q2 2025.
  • Theravance Biopharma's Retained Earnings' 5-year high stood at -$843.5 million during Q3 2022, with a 5-year trough of -$1.8 billion in Q2 2022.
  • Over the past 3 years, Theravance Biopharma's median Retained Earnings value was -$920.8 million (recorded in 2024), while the average stood at -$925.0 million.
  • Per our database at Business Quant, Theravance Biopharma's Retained Earnings decreased by 20.62% in 2021 and then spiked by 50.53% in 2022.
  • Theravance Biopharma's Retained Earnings (Quarterly) stood at -$1.7 billion in 2021, then soared by 50.53% to -$853.9 million in 2022, then decreased by 6.46% to -$909.1 million in 2023, then fell by 6.21% to -$965.5 million in 2024, then rose by 3.09% to -$920.7 million in 2025.
  • Its Retained Earnings stands at -$920.7 million for Q3 2025, versus -$924.3 million for Q2 2025 and -$979.1 million for Q1 2025.